Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS) Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.

Neha Motwani Elected to Longeveron® Board of Directors Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors